NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period†). Savara is a clinical- stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allega. ...

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submissio ...

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your Savara investments, you have until November 7, 2025 to request lead plaintiff appointment. Follow the ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES F. ...

Accessibility StatementSkip Navigation https://zlk.com/pslra-1/savara-inc-lawsuit-submission-form?prid=167315&wire=4 SVRA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) a ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=166911&from=3 CLASS PERIOD: March 4, 2024 to May ...

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action. ...

公司核心产品与业务 - Savara Inc 是一家专注于罕见呼吸系统疾病的临床阶段生物制药公司 [1] - 公司主要候选产品为MOLBREEVI（也称为molgramostim） 这是一种吸入性粒细胞-巨噬细胞集落刺激因子（GM-CSF）[1] 集体诉讼指控内容 - 指控公司在2024年3月7日至2025年5月23日期间误导投资者关于主要候选药物的可行性 [1][2] - 指控未能披露MOLBREEVI生物制剂许可申请缺乏足够的化学、制造和控制信息 [2] - 指控未能披露FDA不太可能以当前形式批准MOLBREEVI的BLA申请 [2] - 指控公司不太可能按向投资者表示的时间框架完成MOLBREEVI的BLA提交 [2] - 指控监管批准延迟增加了公司需要筹集额外资金的可能性 [2] FDA监管回应与市场反应 - 2025年5月27日公司宣布收到FDA拒绝提交（RTF）信件 涉及MOLBREEVI治疗aPap患者的BLA申请 [3] - FDA初步审查确定申请材料不够完整 无法进行实质性审查 要求提供额外的化学、制造和控制相关数据 [3] - 此消息导致公司股价下跌0.90美元/股 跌幅达31.69% 2025年5月27日收盘价为1.94美元/股 [3]

LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Savara, Inc., ("Savara" or the "Company") (NASDAQ: SVRA) investors of a class action on behalf of investors that bought securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). Savara investors have until November 7th, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). Savara investors have until November 7, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE. ...